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Effectiveness and safety of self-
managed oral anticoagulant 
therapy compared with direct oral 
anticoagulants in patients with 
atrial fibrillation
Erik Lerkevang Grove1,2, Flemming Skjøth  3,4, Peter Brønnum Nielsen3,6, 
Thomas Decker Christensen2,5 & Torben Bjerregaard Larsen3,6
We compared the effectiveness and safety of direct oral anticoagulants (DOAC) vs patient self-managed 
warfarin therapy (PSM) in patients with atrial fibrillation. We linked prospectively registered data from 
university hospital clinics to nationwide Danish health registries. Primary effectiveness and safety 
outcomes were ischaemic stroke (incl. systemic embolism) and major bleeding. All-cause mortality and 
all-cause stroke were secondary outcomes. An inverse probability of treatment propensity-weighted 
approach was applied to adjust for potential confounding. The study cohorts included 534 patients 
treated with PSM and 2,671 patients treated with DOAC. Weighted rates of ischaemic stroke were 
0.46 and 1.30 percent per year with PSM vs DOAC, hazard ratio (HR) 0.27 (95% confidence interval 
0.11–0.68) with 2.5 years follow-up. Rates of major bleeding were 2.32 and 2.13 percent per year (HR 
1.06 [0.69–1.63]). All-cause mortality was not statistically different (HR 0.67 [0.39–1.17]), whereas 
the incidence of all-cause stroke was significantly lower among patients treated with PSM with rates 
of 0.61 vs 1.45 percent per year (HR 0.36 [0.16–0.78]). In patients with atrial fibrillation, self-managed 
oral anticoagulant treatment was associated with a significantly lower risk of all-cause and ischaemic 
stroke compared to treatment with DOAC, whereas no significant differences were observed for major 
bleeding and mortality.
Atrial fibrillation (AF) increases the risk of stroke by a factor of 4–5 and accounts for almost 15% of all ischaemic 
strokes1. Several studies have demonstrated that the risk of stroke is reduced by oral anticoagulant therapy with 
vitamin K antagonists (VKA), such as warfarin, or with direct oral anticoagulants (DOAC), also known as non–
VKA oral anticoagulants (dabigatran, rivaroxaban, apixaban, and edoxaban)2–6. Accordingly, oral anticoagulant 
treatment, with either VKA or DOAC, remains the optimal approach to reduce the risk of stroke in patients with 
AF. International guidelines for the management of AF recommend initiation of DOAC over VKA in patients 
who are eligible for both7,8. Furthermore, switching from VKA to DOAC is recommended when the quality of 
anticoagulation control with warfarin is suboptimal7.
Patients on VKA are regularly monitored, and their doses adjusted to ensure that the International Normalised 
Ratio (INR) scores remain in the therapeutic range. However, this is often challenging due to variation in individ-
ual responses and the narrow therapeutic window of warfarin. Point-of-care devices, allowing self-testing of INR 
with a drop of whole blood, facilitate optimised management by offering frequent INR measurements and reduce 
the need for attending anticoagulation clinics. Patient self-management (PSM) is a model empowering trained 
patients to monitor and adjust their treatment in home settings. This strategy has proved effective and convenient 
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compared to conventional treatment with VKA9,10. We have recently reported better effectiveness and similar 
safety in patients with mechanical heart valves11 and patients on long-term anticoagulant treatment after recur-
rent venous thromboembolism (VTE)12. Although AF is the most frequent indication for OAC, studies compar-
ing high-quality warfarin treatment with DOAC is lacking. We aimed to compare the effectiveness and safety 
of self-managed OAC and treatment with DOAC for stroke prevention in a real-life setting of patients with AF.
Materials and Methods
This was an observational cohort study investigating warfarin-treated AF patients assigned to PSM compared 
with matched DOAC-treated patients using Danish registry data.
Patients and data collection. We studied AF patients assigned to PSM at Center for Self-Managed Oral 
Anticoagulation, Department of CardioThoracic and Vascular Surgery, Aarhus University Hospital enrolled 
between 1 June 1996 and the 30 June 2012, and at Center of Thrombosis, Aalborg University Hospital enrolled 
between the 1 April 2008 and 31 December 2012. Each center recorded information on treatment indication, 
training, initiation of PSM, and INR measurements. Database parameters and patient training have previously 
been described in detail13,14. In brief, patients were educated to monitor the INR and adjust the VKA dose accord-
ingly to achieve a designated target INR range. We compared these patients to similar patients with AF treated 
with dabigatran etexilate (approved for AF August 2011), rivaroxaban (approved for AF February 2012) or apix-
aban (approved for AF August 2012).
We used the unique civil registration number assigned to all Danish citizens15 to link data from three nation-
wide registries to obtain a dataset on patient treatment and comorbidity. Data on exposure to anticoagulant 
therapy and concomitant medications was obtained from the Danish National Prescription Registry16, which 
holds purchase date, Anatomical Therapeutic Chemical classification codes, and package size for every redeemed 
prescription in Denmark since 1994. Data on patient comorbidities and outcomes was obtained from the Danish 
National Patient Register17, which contains admission/discharge dates and International Classification of Diseases 
diagnoses for >99% of somatic hospital admissions in Denmark since 1977. Finally, demographic information 
was obtained from the Danish Civil Registration System15, which contains information on sex, date of birth, vital 
status, and emigration status.
Study design. The study was conducted as a propensity-weighted cohort study. To qualify for enrolment in 
the PSM programme, patients should have non-valvular AF and be experienced with OAC treatment. The time 
of PSM initiation was baseline for this group. A control cohort was extracted from the population of Danish 
patients initiating DOAC treatment with either dabigatran etexilate 110 mg or 150 mg BID, rivaroxaban 15 mg or 
20 mg OD, or apixaban 2.5 mg or 5 mg BID, with prior hospital diagnoses for non-valvular AF. Time of DOAC 
initiation was considered as baseline and was required to be within the period 1 January 2012 and 30 June 2014, 
thus avoiding inclusion of control patients initiated early after approval of dabigatran, when selective prescribing 
may have occurred.
As PSM patients are experienced VKA patients at enrolment, we also required that DOAC patients were 
switched from VKA with at least one VKA prescription within one year prior to initiating treatment with DOAC. 
Patients with prior hospital discharge codes for mitral stenosis or valvular replacement surgery indicating valvu-
lar AF were excluded. Previous studies have indicated that PSM patients represent a patient cohort with a rela-
tively low comorbidity11,12. To reduce the risk of selection bias, we therefore restricted the control population to 
patients without comorbidity known to be associated with higher mortality, such as heart failure, cancer, chronic 
pulmonary disease or a Charlson index >2.
To control for possible confounding, we applied an inverse probability of treatment weighted (IPTW) analysis 
with weights defined to estimate the average treatment effect of the treated with focus on the PSM cohort18,19. The 
weights were based on the propensity score for self-managed OAC estimated using logistic regression. Predefined 
indicators of comorbidity and medication were included as predictors in the propensity model, and further risk 
strata were defined by the combination of sex, age (18–65, 65–75, >75 years of age) and OAC experience as 
duration (0–0.5, 0.5–1, 1–5, >5 years) between the first prescription of VKA and baseline. Indicators of disease 
burden were: CHA2DS2-Vasc and Charlson scores, prior bleeding, diabetes, peripheral artery disease, myocar-
dial infarction, renal impairment, prescription redeemed within one year of acetylsalicylic acid, nonsteroidal 
anti-inflammatory drugs, treatment for hypertension, statins, amiodarone, proton pump inhibitors, digoxin or 
ACE-ARB inhibitor. We also required that each risk stratum should include at least one PSM patient and at least 
five eligible controls.
The study was approved by the Danish Data Protection Agency (ref. 2015-57-0001). Ethical approval and 
individual consent are not required for registry-based studies in Denmark. Data from the national registries was 
provided by Statistics Denmark.
Outcome measures and comorbidity. The clinical outcome measures were ischaemic stroke (including 
systemic embolism), major bleeding (intracranial bleeding, gastrointestinal bleeding, various major bleedings 
or traumatic intracranial bleeding), all-cause stroke (ischaemic stroke, systemic embolism or intracranial bleed-
ing) and all-cause death. ICD codes are listed in supplementary Table 1. To assess for possible inclusion bias, we 
applied a falsification analysis by investigating the endpoint of fractures of any type (hip, arms, or legs) as well as 
urinary tract infections: It was expected that these events were neither associated with the drugs investigated, nei-
ther with a time trend during the observation period (1998–2015). All hospital discharge data for endpoints were 
required to be primary or secondary diagnoses, non-ambulatory and non-emergency room codes. A follow-up 
of 2.5 years was applied for the analyses.
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Baseline comorbidity was described according to medication and/or history of hospital discharge data. A 
prescription within one year before date of inclusion was used as indication of treatment. Both primary and 
secondary hospital discharge data back to 1994 was used for baseline comorbidity, when the ICD revision 10 
was introduced. Briefly, comorbidity information consisted of cardiovascular and metabolic diseases, and we 
also collected data to establish the CHA2DS2-Vasc stroke risk score, the HAS-BLED bleeding risk score as well as 
Charlson’s score for overall comorbidity (supplementary Tables 1 and 2).
Statistics. Patient characteristics at baseline are presented as proportions for discrete variables and means 
(SD) for continuous variables. The feasibility of obtaining unbiased estimates through the IPTW analysis by 
aligning baseline characteristics was evaluated by computing standardised differences in both the unweighted 
and weighted samples with standardised differences below 0.1 considered acceptable20. Person-time for DOAC 
patients and PSM patients were counted from initiation of treatment with DOAC and PSM, respectively, until 
the event of interest or 31 December 2015, emigration or death, whichever came first. Clinical endpoints are 
described by weighted incidence event rates calculated as number of events divided by weighted person-time at 
risk and by plotting Kaplan-Meier curves of mortality, and the cumulative incidence function (Aalen-Johansen) 
by time at risk for stroke and bleeding assuming death as a competing risk. Event rates among PSM patients were 
compared with the DOAC group and reported as hazard ratios (HR) estimated by weighted Cox proportional 
hazards models stratified according to the risk strata (defined above).
Patients with renal impairment and increased risk of bleeding are recommended to use low dose DOAC, and 
this may reflect a selected patient group with comorbidity not available in the registries21. We therefore repeated 
the analyses restricted to patients on standard dose DOAC. Furthermore, to ascertain the robustness of our ana-
lytic approach, we repeated the analysis as a 1:2 propensity nearest neighbour matched analysis and as a classical 
adjusted analysis, both using the coarsened exact match strata established above22.
Effect estimates were reported with 95% confidence intervals, and p-values < 0.05 were considered statistically 
significant. Analyses were performed using STATA version 14 (StataCorp LP, TX, USA). Author FS had full access 
to all data in the study and takes responsibility for its integrity and the data analysis.
Results
The study population comprised 2,671 patients in the DOAC group and 534 in the PSM group. The proportion 
with full 2.5 years potential follow-up among DOAC users was 58%, whereas by design all PSM patients had full 
potential follow-up. In the DOAC group, 68% of patients started treatment with dabigatran, 23% with rivarox-
aban and 9% with apixaban. Within 2.5 years, 20% of the DOAC patients redeemed a prescription for warfarin at 
least once. In the PSM group, the number of patients switching to DOAC was low, mainly as the end of 2.5 years 
of follow-up was reached before introduction of DOACs for AF.
During the inclusion period, a total of 575 self-managed patients with AF were identified at Aarhus University 
Hospital and Aalborg University Hospital of which 37 had additional indications for OAC, such as VTE or val-
vular AF, and were thus excluded. A total of 13,549 patients with AF initiated a DOAC in the inclusion period. 
Among these, we excluded patients due to prior VTE (N = 1,205), valvular AF (N = 404), more than one OAC 
type initiated (N = 35) or no prior warfarin use (N = 5,051). In the DOAC population, a total of 3,882 patients 
were identified with diagnostic information related to diseases with an expected poor prognosis (heart failure, 
cancer, chronic pulmonary disease) or high comorbidity as indicated by a Charlson score >2. Eventually, we 
removed risk strata with no cases or less than five eligible controls (N = 295 of which four were cases, Fig. 1).
Unweighted baseline characteristics and demographics of the study population are shown in Table 1. The 
selected DOAC population was older and with a higher proportion of patients with prior bleeding, slightly more 
with hypertension and use of proton pump inhibitors. The PSM population included 20.4% with indication of 
heart failure, and patients with cancer (all types including any previous cancers) or chronic pulmonary dis-
ease accounted for 9.7% and 2.2%, respectively. By design, these patients were excluded in the DOAC cohort.. 
Standardised differences in the unweighted and the IPTW population are shown in Fig. 2. Among >20 standard-
ised differences, two weighted parameters remained slightly above 0.1: the CHA2DS2-Vasc stroke risk score and 
Charlson’s comorbidity score for overall comorbidity. As detailed in Table 1, the CHA2DS2-Vasc score was slightly 
higher among patients treated with PSM, whereas Charlson score was slightly lower. Overall, Fig. 2 indicate that 
the differences between the treatment groups are efficiently reduced in the IPTW population.
Risk profiles in terms of cumulative incidence are presented in Fig. 3, highlighting the low incidence of ischae-
mic stroke among PSM patients as only six events were observed. The risk of a major bleeding event approached 
6% at follow-up after 2.5 years for both PSM and the comparable (weighted) DOAC population. Very few deaths 
were observed among the PSM patients during the first 1.5 years of PSM treatment; after 2.5 years, mortality 
approached 4%, which was slightly below the comparable DOAC population.
At follow-up after 2.5 years, ischaemic stroke was observed with a rate of 0.5 per 100 person years among PSM 
patients (Table 2). This was significantly lower than in the DOAC group (HR 0.27 (95% CI 0.11–0.68). Major 
bleeding was observed at a weighted rate of about 2.3 in both groups, thus comparable with a HR of 1.06 (95% 
CI 0.69–1.63). The combined ischaemic and hemorrhagic all-cause stroke outcome was lower in PSM group 
with weighted rates 0.61 vs 1.45 in the DOAC group (HR 0.36 95% CI 0.16–0.78). The analysis of all-cause death 
showed a rate of 1.1 per 100 person years among PSM patients, whereas the rate in the DOAC group was 1.3, cor-
responding to a HR of 0.67 (95% CI 0.39–1.17). A landmark analysis obtained by restricting the survival analysis 
to patients alive one year after inclusion resulted in a HR of 1.09 (95% CI 0.57–2.09).
The falsification analysis of the two control outcomes, fractures and urinary tract infection, displayed lower 
rates among the PSM patients, but both with unity within the confidence intervals of the HRs.
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During the 2.5 years of follow-up, a total of 23 and only two intracranial bleedings were observed in the 
DOAC and PSM groups, respectively. In the weighted cohorts, these numbers corresponded to rates of 0.19 and 
0.15. Due to low number of events, we did not further explore this difference.
Table 3 shows hazard ratios for endpoints contrasting DOAC vs PSM cohorts after additional sensitivity anal-
yses with findings similar to the ones summarised above. Accordingly, treatment with PSM compared to DOAC 
was associated with a significantly lower risk of both all-cause and ischaemic stroke, whereas no difference was 
observed for major bleeding. The risk of death was numerically lower in the PSM group.
Increasing the proportion of DOAC patients with full 2.5 years potential follow-up by using an earlier date 
for stop of inclusion did not alter the results substantially. Neither did restriction to patients treated with stand-
ard dose DOAC. Altering the analytical approach by using 1:2 direct matching or traditional adjusted analyses 
resulted in comparable rates and HRs.
Discussion
This is the largest cohort study evaluating self-managed treatment with VKA in patients with AF. Using pro-
pensity weights to account for differences in comorbidity, we compared the effectiveness and safety of DOAC 
versus self-managed anticoagulant treatment with VKA in patients with AF and have shown that PSM of properly 
trained patients is safe and effective in a real-life setting. We found that a strategy of PSM was associated with 
a significantly lower risk of both ischaemic and all-cause stroke compared to treatment with DOAC, whereas 
no significant differences were observed for major bleeding and mortality. These novel findings indicate that 
self-managed OAC with VKA should be considered more frequently as an anticoagulant strategy for patients with 
AF. When interpreting these results it should be acknowledged that falsification analyses indicated a risk of some 
residual confounding. Moreover, not all patients with AF are eligible for self-managed oral anticoagulation23.
Oral anticoagulant treatment remains the preferred strategy to reduce the risk of stroke in patients with AF, 
and international guidelines recommend initiation of DOAC instead of VKA in patients who are eligible for 
both7,8. Two classes of DOAC are available: direct thrombin inhibitors (dabigatran) and factor Xa inhibitors (e.g. 
rivaroxaban and apixaban). All these drugs have shown at least non-inferiority to conventionally managed VKA 
treatment24, and in some cases superior efficacy for the primary endpoint of ‘stroke and systemic embolism’ 
(dabigatran 150 mg twice daily + apixaban)3,4. In our study, PSM was associated with a significantly lower risk of 
all-cause stroke and systemic embolism and also a lower risk of ischaemic stroke.
The safety and efficacy of self-managed treatment with VKA has been the subject of several clinical trials. 
A meta-analysis of individual patient data from 11 trials showed that PSM is a safe option for suitable patients 
with a significant reduction in thromboembolic events compared to conventionally managed VKA9. In 2017, a 
comprehensive systematic review of 28 studies concluded that compared to conventionally managed VKA, PSM 
was associated with a significant reduction in thromboembolic events (RR 0.58; 95% CI 0.45–0.74), with no sig-
nificant effects on bleeding or all-cause mortality10. The findings of our study are consistent with this conclusion; 
however, in the systematic review only 2 studies included patients with AF, thus stressing the need for more data 
on PSM in patients with AF.
Even more important is the fact that there is a clear need for studies comparing PSM with DOAC, since both 
anticoagulant strategies have proved superior to conventionally managed VKA3–6,9. Contrary to the solid evidence 
for treatment with either PSM or DOAC, no studies have directly compared these treatment strategies in patients 
Figure 1. Flowchart of patient inclusion. AC: anticoagulant; AF: atrial fibrillation; DOAC: direct oral 
anticoagulant; PSM: Patient self-management group; VKA: vitamin-K antagonist.
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with AF. A previous network meta-analysis concluded that the efficacy of PSM is comparable to VKA standard 
care and DOAC, but this analysis only included 203 patients with AF25. Similarly, an indirect comparison of 
dabigatran with home-monitoring (self-testing + PSM) suggested that these anticoagulant strategies have similar 
impact on thrombosis, bleeding and mortality, although with confidence in the estimate of effect being ‘low to 
very low’26. Our study adds to the growing evidence supporting PSM as an important option in patients with AF.
Intracranial bleeding is the most feared and devastating complication of anticoagulant treatment, because 
it carries a very high risk of morbidity and mortality27. Importantly, treatment with DOAC in phase III trials of 
patients with AF was associated with a significantly lower risk of intracranial bleeding, regardless of the type and 
dose of DOAC tested28. In our study, the risk of intracranial bleeding was low in both groups, but numerically 
lower in the PSM group. It is well-known that the risks of VKA-associated intracranial bleeding are propor-
tional to the intensity of anticoagulation29, and the low risk of intracranial bleeding in PSM patients is at least 
partly explained by the high quality of anticoagulant control with INR values within the target range in >70% of 
patients14.
The reason for the similar rate of major bleeding events during PSM and DOAC is likely multifaceted. 
Although PSM is a high quality VKA treatment in terms of time in therapeutic range14, it is known that the major-
ity of bleeding events occur within therapeutic range30. Furthermore, the rigorous monitoring of PSM patients 
likely results in improved adherence compared to patients receiving usual care with VKA or DOAC31. Finally, 
when interpreting the absolute risk of bleeding, it should be acknowledged that this is likely to be lower in patients 
included after several years of anticoagulant treatment.
Within recent years, there has been a large increase in the use of DOAC for thromboprophylaxis in patients 
with AF32,33. This is consistent with international guidelines7,8, and is explained by the favourable results in phase 
III trials with at least similar efficacy as VKA and a lower risk of major bleeding, especially intracranial bleeding3–6. 
Also, there are fewer drug interactions than for VKA, and the predictable pharmacology eliminates the need for 
laboratory monitoring of the anticoagulant effect and frequent dose adjustments, and DOAC thus provides a safe 
and convenient alternative to conventionally managed treatment with VKA. One may therefore question if PSM 
with point-of-care devices is still a viable treatment option. However, not all patients are eligible for DOAC, if 
Variable
Self-management 
group
DOAC group 
unweighted
DOAC group ATT 
weighted
Number of patients 534 2671 2671
2.5 years potential follow-up, % (N) 100 (534) 57.7 (1542) 61.9 (328)
Female sex, % (N)§ 23.6 (126) 37.7 (1008) 23.6 (126)
Age, mean (SD)§ 63.1 (7.4) 71.6 (10.3) 63.7 (8.2)
Age ≥ 65years, % (N) 43.1 (230) 76.5 (2043) 42.5 (227)
Age ≥ 75years, % (N) 4.1 (22) 36.4 (971) 4.1 (22)
Duration of prior VKA therapy, months, mean (SD)§ 32.5 (34.1) 41.8 (46.8) 38.3 (42.8)
CHA2DS2-Vasc stroke risk score, mean (SD) 2.2 (1.4) 2.8 (1.5) 1.9 (1.4)
HAS-BLED bleeding score, mean (SD) 1.9 (1.1) 2.3 (1.1) 1.9 (1.2)
Charlson score, mean (SD) 0.8 (1.1) 0.5 (0.7) 0.6 (0.8)
Prior stroke, % (N) 18.2 (97) 20.7 (629) 18.4 (98)
Prior bleeding, % (N) 11.8 (63) 17.6 (469) 11.5 (61)
Hypertension, % (N) 62.9 (336) 60.7 (1622) 61.4 (327)
Diabetes, % (N) 10.9 (58) 12.4 (331) 9.8 (52)
Myocardial infarction, % (N) 9.0 (48) 6.4 (170) 8.9 (47)
Peripheral artery disease, % (N) 3.4 (18) 5.4 (143) 3.2 (17)
Moderate/severe kidney impairment, % (N) 2.6 (14) 1.3 (35) 4.0 (21)
Heart failure, % (N) 20.4 (109) 0.0 (0)⤈ 0.0 (0)⤈
Cancer, % (N) 9.7 (52) 0.0 (0)⤈ 0.0 (0)⤈
Chronic obstructive pulmonary disease, % (N) 2.2 (12) 0.0 (0)⤈ 0.0 (0)⤈
Aspirin, % (N) 36.5 (195) 29.2 (708) 36.6 (195)
NSAIDs, % (N) 20.2 (108) 19.2 (514) 19.7 (105)
Statins, % (N) 45.7 (244) 46.4 (1239) 44.6 (237)
Beta-blocker, % (N) 73.4 (392) 69.5 (1875) 72.2 (384)
Proton pump inhibitor, % (N) 15.2 (81) 21.2 (567) 16.2 (86)
Amiodarone, % (N) 14.8 (79) 6.3 (167) 14.0 (75)
Digoxin, % (N) 30.5 (163) 23.9 (638) 29.0 (155)
ACE or ARB inhibitors, % (N) 54.3 (290) 44.2 (1180) 53.4 (285)
Table 1. Baseline characteristics for DOAC and self-management groups. §Variables used for coarsened exact 
match. ⤈Excluded by design. ACE/ARB: Angiotensin converting enzyme inhibitors, angiotensin II receptor 
blockers; ATT: Average treatment effect of the treated; DOAC: Direct oral anticoagulant; SD: Standard 
deviation; NSAID: Nonsteroidal anti-inflammatory drugs; CHA2DS2-Vasc: stroke risk score; HAS-BLED: 
bleeding risk score.
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e.g. patients have severe renal failure, mechanical heart valves or a considerably increased risk of gastrointestinal 
bleeding. Importantly, one should also consider PSM to some patients eligible for treatment with DOAC. PSM 
seems to be cost-effective34 and, compared to conventional VKA treatment, it is associated with a higher patient 
satisfaction with OAC and quality of life35,36.
Strengths and limitations. The two-center inclusion and the long-term follow-up are important strengths, 
and a high external validity of our data is likely. All AF patients referred for PSM in the study period were 
included. Our comparator group was sampled from the entire Danish population and had complete follow-up 
through nationwide registries, thus avoiding the selection bias traditionally hampering clinic-based studies. 
Baseline characteristics of the unmatched cohorts of PSM and DOAC users were largely comparable, and did thus 
not indicate major differences in prescribing patterns. Selection of patients for PSM is dependent on the referral 
pattern, however this selection bias is limited because the cost of PSM in Denmark is reimbursed for all patients. 
Limitations of our study mainly relate to its observational nature and the relatively low number of patients, 
which e.g. did not allow for comparison of effectiveness and safety across different DOACs. Although we applied 
Standardized difference
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Figure 2. Standardised baseline differences before and after IPTW analysis. ACE/ARB, angiotensin converting 
enzyme inhibitors/angiotensin II receptor blockers IPTW, inverse probability of treatment weighted, NSAIDs, 
nonsteroidal anti-inflammatory drugs PAD, peripheral artery disease.
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Figure 3. Cumulative incidence functions for ischaemic stroke, bleeding and death. Ischaemic stroke includes 
systemic embolism. DOAC: direct oral anticoagulant; PSM: Patient self-management group.
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Events 
N
Crude event rate 
(%/year)
IPTW ATT event rate 
(%/year)
IPTW ATT hazard ratio 
(HR) (95% CI)
Ischaemic stroke incl SE
DOAC 134 2.36 1.30 Reference
PSM 6 0.46 0.46 0.27 (0.11–0.68)
Major bleeding
DOAC 211 3.79 2.13 Reference
PSM 30 2.32 2.32 1.06 (0.69–1.63)
All-cause stroke
DOAC 153 2.71 1.45 Reference
PSM 8 0.61 0.61 0.36 (0.16–0.78)
All-cause death
DOAC 228 3.92 1.32 Reference
PSM 15 1.13 1.13 0.67 (0.39–1.17)
Fractures (control outcome)
DOAC 174 3.09 1.78 Reference
PSM 18 1.37 1.37 0.78 (0.45–1.36)
Urinary tract infection (control outcome)
DOAC 114 2.00 0.71 Reference
PSM 7 0.53 0.53 0.64 (0.27–1.52)
Landmark analysis, All-cause death after one year in study
DOAC 115 3.92 1.0 Reference
PSM 14 1.77 1.77 1.09 (0.57–2.09)
Table 2. Event rates and hazard ratios for endpoints in DOAC and PSM cohorts after 2.5 years of follow-up. 
ATT = average treatment on the treated (self-management group); CI: Confidence Interval; DOAC: direct 
oral anticoagulant; HR: Hazard Ratio; IPTW = Inverse probability of treatment weighting; PSM: Patient self-
management group; SE: systemic embolism.
Main analysis IPTW ATT 
hazard ratio (HR) (95% CI)
Propensity matched 1:2 hazard 
ratio (H) (95% CI)
Standard dose IPTW ATT 
hazard ratio (HR) (95% CI)
Adjusted hazard ratio 
(HR) (95% CI)
Ischaemic stroke incl SE
DOAC Reference Reference Reference Reference
PSM 0.27 (0.11–0.68) 0.28 (0.12–0.67) 0.28 (0.10–0.77) 0.26 (0.11–0.57)
Major bleeding
DOAC Reference Reference Reference Reference
PSM 1.06 (0.69–1.63) 0.89 (0.57–1.38) 0.97 (0.57–1.64) 1.00 (0.70–1.44)
All-cause stroke
DOAC Reference Reference Reference Reference
PSM 0.36 (0.16–0.78) 0.34 (0.16–0.72) 0.38 (0.16–0.91) 0.33 (0.16–0.65)
All-cause death
DOAC Reference Reference Reference Reference
PSM 0.67 (0.39–1.17) 0.71 (0.39–1.31) 0.83 (0.38–1.85) 0.76 (0.46–1.26)
Fractures (control outcome)
DOAC Reference Reference Reference Reference
PSM 0.78 (0.45–1.36) 0.81 (0.46–1.41) 0.76 (0.40–1.843) 0.76 (0.46–1.21)
Urinary tract infection (control outcome)
DOAC Reference Reference Reference Reference
PSM 0.64 (0.27–1.52) 0.43 (0.19–0.99) 0.58 (0.20–1.68) 0.66 (0.31–1.39)
Landmark analysis, All-cause death after one year in study
DOAC Reference Reference Reference Reference
PSM 1.09 (0.57–2.09) 1.06 (0.53–2.10) 1.34 (0.51–3.50) 1.23 (0.72–2.09)
Table 3. Hazard ratios for endpoints in DOAC and PSM cohorts after sensitivity analyses and 2.5 years 
follow-up. ATT = average treatment on the treated (self-management group); CI: Confidence Interval; DOAC: 
direct oral anticoagulant; HR: Hazard Ratio; IPTW = Inverse probability of treatment weighting; PSM: Patient 
self-management group; SE: systemic embolism.
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propensity weighting to account for baseline differences and differential prescribing behavior, some residual and 
unmeasured confounding may persist as indicated by the falsification endpoint analyses. Our estimates of effec-
tiveness and safety are based on propensity-weighting conducted in a setting with free access to health services, 
thus largely eliminating e.g. referral bias. We had no access to laboratory, anthropometric, or socioeconomic data. 
We also lacked data on lifestyle factors such as alcohol consumption and smoking that may influence outcomes 
in patients with AF. However, we were able to control for hospital diagnoses of alcohol-related conditions and 
many other lifestyle-related diseases including diabetes, cardiovascular disease, and chronic pulmonary diseases, 
which to some extent serve as markers of the above-mentioned lifestyle factors. Finally, sensitivity analyses did 
not change conclusions, suggesting high internal validity.
Conclusions
Self-managed OAC was associated with a lower risk of ischaemic and all-cause stroke compared to treatment with 
DOAC, whereas no significant differences were observed for major bleeding and mortality. This study shows that 
in properly trained patients, self-managed OAC could be an effective and safe alternative to DOAC as long-term 
anticoagulant treatment for stroke prevention in patients with AF. These findings should be confirmed in a ran-
domised controlled trial.
Data Availability
The datasets analysed for this study are available from the corresponding author upon reasonable request.
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